 | Up a level |
Riek, Myriam; Scherer, Almut; Möller, Burkhard; Ciurea, Adrian; von Mühlenen, Ines; Gabay, Cem; Kyburz, Diego; Brulhart, Laure; von Kempis, Johannes; Mueller, Ruediger B; Hasler, Paul; Strahm, Tanja; von Känel, Sabine; Zufferey, Pascal; Dudler, Jean; Finckh, Axel (2023). Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Scientific Reports, 13(1), p. 17776. Nature Publishing Group 10.1038/s41598-023-44841-w
Kiener, Sarah; Ribi, Camillo; Keller, Irene; Chizzolini, Carlo; Trendelenburg, Marten; Huynh-Do, Uyen; von Kempis, Johannes; Leeb, Tosso (2021). Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. Genes, 12(8), p. 1268. MDPI 10.3390/genes12081268
Chaigne, Benjamin; Chizzolini, Carlo; Perneger, Thomas; Trendelenburg, Marten; Huynh-Do, Uyen; Dayer, Eric; Stoll, Thomas; von Kempis, Johannes; Ribi, Camillo (2017). Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC immunology, 18(1), p. 17. BioMed Central 10.1186/s12865-017-0200-5
Mueller, Ruediger B; Gengenbacher, Michael; Richter, Symi; Dudler, Jean; Möller, Burkhard; von Kempis, Johannes (2016). Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Arthritis research & therapy, 18(88), p. 88. BioMed Central 10.1186/s13075-016-0985-2
von Kempis, Johannes; Dudler, Jean; Hasler, Paul; Kyburz, Diego; Tyndall, Alan; Zufferey, Pascal; Villiger, Peter M (2012). Use of abatacept in rheumatoid arthritis. Swiss medical weekly, 142, w13581. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2012.13581
Walker, Ulrich A; Courvoisier, Delphine S; Dudler, Jean; Aeberli, Daniel; von Kempis, Johannes; Scherer, Almut; Finckh, Axel; on behalf of the, Swiss Clinical Quality Management Programme in Rheumatic Disease (2011). Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. Rheumatology, 50(1), pp. 243-244. Oxford: Oxford University Press 10.1093/rheumatology/keq258
